Trial Profile
A Phase IIIb, Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory, Single-dose Crossover Study With Indacaterol 75 microgram Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2013
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 24 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 31 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2012 New trial record